Document Detail

Exercise, Stress Resistance, and Central Serotonergic Systems.
MedLine Citation:
PMID:  21508844     Owner:  NLM     Status:  Publisher    
Voluntary exercise reduces the incidence of stress-related psychiatric disorders in humans and prevents serotonin-dependent behavioral consequences of stress in rodents. Evidence reviewed herein is consistent with the hypothesis that exercise increases stress resistance by producing neuroplasticity at multiple sites of the central serotonergic system which all help to limit the behavioral impact of acute increases in serotonin during stressor exposure.
Benjamin N Greenwood; Monika Fleshner
Related Documents :
1609584 - Polyethylene wear in unicondylar knee prostheses. 106 retrieved marmor, pca, and st geo...
7053884 - Exercise testing in patients with variant angina: results, correlation with clinical an...
1733674 - Equalization of z and w axes in chicken and quail oocytes.
12488654 - Diagnostic value of simultaneous non-invasive continuous, ambulatory finger blood press...
12451004 - Role of nondiagnostic exercise-induced st-segment abnormalities in predicting future co...
7826814 - Zinc content in selected tissues in streptozotocin-diabetic rats after maximal exercise.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-4-19
Journal Detail:
Title:  Exercise and sport sciences reviews     Volume:  -     ISSN:  1538-3008     ISO Abbreviation:  -     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-4-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0375434     Medline TA:  Exerc Sport Sci Rev     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Integrative Physiology and Center for Neuroscience, University of Colorado-Boulder, Boulder, CO 80309-0354.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  New treatment targets in ankylosing spondylitis and other spondyloarthritides.
Next Document:  Plasma catecholamine release-inhibitory peptide catestatin in patients with essential hypertension.